Resistant Hypertension

DANA POINT, Calif. — In this Healio video exclusive, Keith C. Ferdinand, MD, discusses resistant hypertension, which he said “is the most powerful and potent cardiovascular risk factor in women.”

Winter-induced elevations in BP were persistent among patients with hypertension despite treatment with up to three classes of antihypertensive medications, with an approximately 7% drop in BP control, researchers reported.

Renal denervation lowered blood pressure out to 36 months, regardless of baseline antihypertensive class combinations and polypharmacy burden, according to an analysis of the Global SYMPLICITY Registry DEFINE.

PHILADELPHIA — A variety of pharmacologic and device-based approaches provides hope for effective and safe treatment of resistant hypertension, which can be “tedious but important” to diagnose, according to a speaker.

In Black patients with resistant hypertension, renal denervation was associated with reductions in systolic BP at 3 years, according to new data from the SYMPLICITY HTN-3 trial.

There was a sustained reduction in ambulatory BP out to 9 years in patients who underwent renal denervation for resistant hypertension, according to a study published in Hypertension.

Efficacy and safety of multiple dose strengths of baxdrostat vs. placebo in treatment-resistant hypertension.

Efficacy and safety of firibastat vs. placebo in adults with uncontrolled primary hypertension.

CHICAGO — Baxdrostat, an aldosterone synthase inhibitor, yielded substantial dose-related decreases in BP in patients with treatment-resistant hypertension, according to results from the phase 2 BrigHtn trial.

CHICAGO — Aprocitentan, a dual endothelin antagonist, was superior to placebo for BP lowering and was well tolerated in patients with resistant hypertension, according to results of the PRECISION trial.